Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma

Pathology ◽  
2019 ◽  
Vol 51 (7) ◽  
pp. 688-695 ◽  
Author(s):  
Kartik Vasan ◽  
Laveniya Satgunaseelan ◽  
Sunaina Anand ◽  
Rebecca Asher ◽  
Christina Selinger ◽  
...  
2020 ◽  
Vol 122 (8) ◽  
pp. 1755-1760
Author(s):  
Kartik Vasan ◽  
Sunaina Anand ◽  
Laveniya Satgunaseelan ◽  
Rebecca Asher ◽  
Hubert Low ◽  
...  

2001 ◽  
Vol 439 (5) ◽  
pp. 622-627 ◽  
Author(s):  
Sheng-Ben Liang ◽  
Mutsuo Furihata ◽  
Tamotsu Takeuchi ◽  
Hiroshi Sonobe ◽  
Yuji Ohtsuki

Pathobiology ◽  
2019 ◽  
Vol 86 (2-3) ◽  
pp. 145-151 ◽  
Author(s):  
Robert Stoehr ◽  
Olaf Wendler ◽  
Johannes Giedl ◽  
Nadine T. Gaisa ◽  
Georg Richter ◽  
...  

2015 ◽  
Vol 04 (04) ◽  
pp. 183-185 ◽  
Author(s):  
Karan Gupta ◽  
Naresh K Panda ◽  
Jaimanti Bakshi ◽  
Ashim Das

Abstract Background: Accurate clinical staging is important for patient counseling, treatment planning, prognostication, and rational design of clinical trials. In head and neck squamous cell carcinoma, discrepancy between clinical and pathological staging has been reported. Objective: To evaluate any disparity between clinical and pathological tumor-node-metastasis (TNM) staging in oral cavity squamous cell carcinoma (OCSCC) patients and any impact of the same on survival. Materials and Methods: Retrospective chart review from year 2007 to 2013, at a tertiary care center. Statistical Analysis: All survival analyses were performed using SPSS for Windows version 15 (Chicago, IL, USA). Disease-free survival curves were generated using Kaplan-Meier algorithm. Results: One hundred and twenty-seven patients with OCSCC were analyzed. Seventy-nine (62.2%) were males and 48 (37.8%) females with a mean age at presentation 43.6 years (29-79 years). The highest congruence between clinical and pathological T-staging seen for clinical stage T1 and T4 at 76.9% and 73.4% with pathological T-stage. Similarly, the highest congruence between clinical and pathological N-stage seen for clinical N0 and N3 at 86.4% and 91.7% with pathological N-stage. Of clinically early stage patients, 67.5% remained early stage, and 32.5% were upstaged to advanced stage following pathological analysis. Of the clinically advanced stage patients, 75% remained advanced, and 25% were pathologically downstaged. This staging discrepancy did not significantly alter the survival. Conclusion: Some disparity exists in clinical and pathological TNM staging of OCSCC, which could affect treatment planning and survival of patients. Hence, more unified and even system of staging for the disease is required for proper decision-making.


Head & Neck ◽  
2014 ◽  
pp. n/a-n/a
Author(s):  
James J. Jaber ◽  
Chad A. Zender ◽  
Vikas Mehta ◽  
Kara Davis ◽  
Robert L. Ferris ◽  
...  

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 41s-41s
Author(s):  
R. Venchiarutti ◽  
J. Clark ◽  
C. Palme ◽  
M. Solomon ◽  
J. Young

Background: Early cancer diagnosis is a critical component of comprehensive cancer control, however more than 50% of head and neck cancers (HNCs) are diagnosed at advanced stage. HNC patients from regional/remote areas are less likely to use radiotherapy during treatment and have poorer survival outcomes than metropolitan patients. Aim: The aim of this study was to examine pathways to treatment of patients with HNC in New South Wales (NSW) and associations between duration of components of the pathway with survival. Methods: Patients diagnosed with squamous cell carcinoma (SCC) of the oral cavity, oropharynx, or cutaneous SCC from 1st July 2008 to 30th June 2013 were identified from a prospectively maintained database. Data were extracted and supplemented by a retrospective audit of medical records at Royal Prince Alfred Hospital and specialists' records. Results: Two hundred and fifty eligible patients were identified (78% male) with mean (SD) age at diagnosis 64.5 (13.5) years. At diagnosis, 75%, 24% and 1% lived in metropolitan, regional and remote areas of NSW, respectively. Twelve per cent of patients lived > 100 km from a hospital with a HNC multidisciplinary team (median [IQR] 7.5 km [25.1]). More than two-thirds (69%) of tumors were diagnosed as advanced stage, and mean follow-up time was 3.5 years. We will present additional findings quantifying intervals along the pathway to treatment (from symptom onset, first specialist visit, diagnosis and treatment), and the associations with survival, and compare findings to those from a second regional site on the mid north coast of NSW. Conclusion: An increasing proportion of the NSW population resides outside major cities. This study is the first step in understanding patient and health system factors that facilitate and impede early diagnosis of HNC. Findings from this study may be used to develop interventions aimed at improving early HNC diagnosis.


Sign in / Sign up

Export Citation Format

Share Document